Information Provided By:
Fly News Breaks for April 6, 2018
PCRX
Apr 6, 2018 | 07:12 EDT
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $72 price target on Pacira Pharmaeuticals ahead of the expected PDUFA date for potential expansion of EXPAREL's label to specify nerve block. In a research note to investors, the analyst said she is "hopeful" that EXPAREL could potentially be used to provide improved outcomes in long-acting regional analgesia compared to infusion pumps or opioids. Whether required post-approval or in preparation for future regulatory review, she sees Pacira to continuing to evaluate EXPAREL in different nerve block techniques.
News For PCRX From the Last 2 Days
There are no results for your query PCRX